Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system

• Published in: Frontiers in pharmacology Vol. 15; p. 1398667
• Main Authors: Bai, Yifeng, Wang, Xiaomei, Dai, Xiaoqin, Ma, Qinghua, Hu, Honglin
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 30.10.2024
• Subjects: adverse (side) effects; FDA adverse event reporting system (FAERS); ICIs; immune check point inhibitors; irAEs (immune-related adverse events); Pharmacology; SCLC; FDA adverse event reporting system (FAERS); SCLC; irAEs (immune-related adverse events); adverse (side) effects; ICIs; immune check point inhibitors

The discovery and development of immune checkpoint inhibitors (ICIs) have resulted in their application as a novel therapeutic strategy for patients with small-cell lung cancer (SCLC). However, a comprehensive analysis of the potential adverse effects of ICIs in patients with SCLC remains to be cond...